Charles River Laboratories (CRL) Q3 revenue $982.7 million vs $968 million est.; adj. EPS $3.09 vs $3.00 est.; raises full-year guidance

Charles River Laboratories reported third-quarter 2026 revenue of $982.7 million and adjusted EPS of $3.09, beating consensus estimates of $968 million and $3.00, respectively. The Wilmington, MA-based contract research organization posted 4.7% organic revenue growth—its second consecutive quarter of organic growth—while non-GAAP operating margin expanded 330 basis points to 23.0% and adjusted EPS rose 27.2% year-over-year. Management raised full-year 2026 guidance, lifting organic revenue growth guidance by 100 basis points and non-GAAP EPS guidance by $0.15 at the midpoint, citing better-than-expected performance in its Discovery and Safety Assessment (DSA) segment and a lower tax rate. The company also unveiled its "Pathway to Purpose" strategic vision and "Create the Future" initiative at its 2026 Investor Day, alongside manufacturing and digital investments including its Endosafe Cartridge Technology Automated Manufacturing Suite and an Apollo platform partnership with Autolomous. Investors will watch whether the DSA-led outperformance and tax benefit prove durable into 2027, and how the newly outlined strategic initiatives translate into margin and growth trajectory.